S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
LON:SAR

Sareum (SAR) Share Forecast, Price & News

GBX 80
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
78
▼
83
50-Day Range
72.50
▼
105.50
52-Week Range
55.10
▼
237.50
Volume
45,724 shs
Average Volume
83,659 shs
Market Capitalization
£56.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 304
ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines

Sareum MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
280.0% Upside
GBX 304 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
£203,278 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SAR stock logo

About Sareum (LON:SAR) Stock

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes TYK2/JAK1 kinase, which is in preclinical stage; Checkpoint Kinase 1, which has completed clinical phase II; and FLT3+Aurora kinase, which is in preclinical stage. The company was founded in 2003 and is headquartered in Cambridge, the United Kingdom.

SAR Price History

SAR Stock News Headlines

September 5, 2023 | msn.com
Sareum doses first subjects in second stage of Phase 1a trial of SDC-1801
September 4, 2023 | lse.co.uk
Sareum begins dosing participants in phase 1a trial for SDC-1801
September 29, 2023 | The Oxford Club (Ad)
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
August 22, 2023 | msn.com
25 Best Netflix Movies Based On True Stories
July 15, 2023 | msn.com
Netflix: The thriller written by Angelina Jolie that is all the rage on the platform in the US
June 26, 2023 | lse.co.uk
TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment
June 22, 2023 | marketwatch.com
A thorough analysis of the Anaplastic Large Cell Lymphoma Treatment market Size with projected 13.7% CAGR growth from 2023 to 2030
June 16, 2023 | ft.com
Fresh blow to City as WE Soda pulls $7.5bn London IPO
September 29, 2023 | The Oxford Club (Ad)
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
May 25, 2023 | finance.yahoo.com
SAR.L - Sareum Holdings plc
May 18, 2023 | lse.co.uk
TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect
April 27, 2023 | finance.yahoo.com
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate
April 17, 2023 | marketwatch.com
NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Size by 2031
April 7, 2023 | marketwatch.com
Non Receptor Tyrosine Protein Kinase TYK2 Market Demand by 2030
March 30, 2023 | uk.news.yahoo.com
Should I get invested in this FTSE pharma share?
March 2, 2023 | marketwatch.com
New Market Report on Anaplastic Large Cell Lymphoma Comes With A Thorough Analysis Of Industry Trends, Share, Size.
February 7, 2023 | finance.yahoo.com
Following a 32% decline over last year, recent gains may please Sareum Holdings plc (LON:SAR) institutional owners
January 23, 2023 | marketwatch.com
NON RECEPTOR TYROSINE PROTEIN KINASE TYK2 Market Evolution Segmentation and Insight of Trends 2023 to 2028 with Top Countries Data
October 25, 2022 | finance.yahoo.com
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
October 14, 2022 | msn.com
SMALL CAP MOVERS: Property lender Lendinvest sinks 36% to a new low of 64p over risk of falling property prices; Cybersecurity firm Intercede surges 39% - msnNOW
October 13, 2022 | lse.co.uk
Glaxosmithkline News Headlines. GSK Share News. Financial News Articles for Gsk Plc Ord 31 1/4P updated throughout the day. - London South East
October 12, 2022 | marketscreener.com
Sareum Plunges 19% Amid GSK Unit's Plan To Return Cancer Medication Rights To CRT Pioneer Fund - Marketscreener.com
October 12, 2022 | lse.co.uk
Nigeria's Forcados crude loadings to restart by end of October - SPDC | Financial News - London South East
October 12, 2022 | marketwatch.com
Sareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall - MarketWatch
September 13, 2022 | proactiveinvestors.com.au
Small Cap Feast - Critical Metals, Nightcap, Sareum Holdings, Spectra Systems, Altona Rare Earths and more... - Proactive Investors Australia
September 13, 2022 | morningstar.co.uk
CORRECT: Sareum notes US FDA approval of Bristol-Myers's Sotyktu - Morningstar
September 12, 2022 | morningstar.co.uk
Sareum receives US US Food & Drug Administration approval for Sotyktu - Morningstar
See More Headlines
Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:SAR
CUSIP
N/A
CIK
N/A
Web
www.sareum.co.uk
Phone
+44-1223-497700
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 304
High Stock Price Forecast
GBX 304
Low Stock Price Forecast
GBX 304
Forecasted Upside/Downside
+280.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-2,760,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-64.48%
Return on Assets
-44.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.22
Quick Ratio
10.37

Sales & Book Value

Annual Sales
£47,204.00
Price / Sales
1,187.53
Cash Flow
GBX 7.06 per share
Price / Cash Flow
11.32
Book Value
GBX 4 per share
Price / Book
20.00

Miscellaneous

Outstanding Shares
70,070,000
Free Float
N/A
Market Cap
£56.06 million
Optionable
Not Optionable
Beta
-0.51
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Tim J. Mitchell Ph.D. (Age 63)
    Founder, CEO & Exec. Director
    Comp: $189.6k
  • Dr. John C. Reader Ph.D. (Age 56)
    Founder, Chief Scientific Officer & Exec. Director
    Comp: $187.14k
  • Mr. Clive H. W. Birch F.C.A. (Age 69)
    Sr. Independent Non-Exec. Director & Sec.
    Comp: $20k
  • Alexandra Harrison
    Head of IR

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













SAR Stock - Frequently Asked Questions

Should I buy or sell Sareum stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sareum in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAR shares.
View SAR analyst ratings or view top-rated stocks.

What is Sareum's stock price forecast for 2023?

1 Wall Street research analysts have issued 1-year price objectives for Sareum's stock. Their SAR share price forecasts range from GBX 304 to GBX 304. On average, they expect the company's stock price to reach GBX 304 in the next twelve months. This suggests a possible upside of 280.0% from the stock's current price.
View analysts price targets for SAR or view top-rated stocks among Wall Street analysts.

How have SAR shares performed in 2023?

Sareum's stock was trading at GBX 82.50 at the beginning of the year. Since then, SAR shares have decreased by 3.0% and is now trading at GBX 80.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Sareum own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP), Madagascar Oil (MOIL), Summit Therapeutics (SMMT), Rockhopper Exploration (RKH) and

What is Sareum's stock symbol?

Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Sareum's stock price today?

One share of SAR stock can currently be purchased for approximately GBX 80.

How much money does Sareum make?

Sareum (LON:SAR) has a market capitalization of £56.06 million and generates £47,204.00 in revenue each year. The company earns £-2,760,000.00 in net income (profit) each year or GBX (0.04) on an earnings per share basis.

How can I contact Sareum?

Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The official website for the company is www.sareum.co.uk. The company can be reached via phone at +44-1223-497700.

This page (LON:SAR) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -